Eli Lilly and Company or Pfizer Inc.: Who Invests More in Innovation?

Eli Lilly's R&D spending surges, challenging Pfizer's lead.

__timestampEli Lilly and CompanyPfizer Inc.
Wednesday, January 1, 201447336000008393000000
Thursday, January 1, 201547964000007690000000
Friday, January 1, 201652439000007872000000
Sunday, January 1, 201752818000007657000000
Monday, January 1, 201850512000008006000000
Tuesday, January 1, 201955950000008650000000
Wednesday, January 1, 202060857000009405000000
Friday, January 1, 2021702590000013829000000
Saturday, January 1, 2022719080000011428000000
Sunday, January 1, 2023931340000010679000000
Monday, January 1, 20241427100000010930000000
Loading chart...

Unveiling the hidden dimensions of data

Innovation Investment: Eli Lilly vs. Pfizer

In the competitive world of pharmaceuticals, innovation is key. Over the past decade, Eli Lilly and Pfizer have been at the forefront of research and development (R&D) spending. From 2014 to 2023, Pfizer consistently outpaced Eli Lilly in R&D investment, with an average annual expenditure of approximately $9.4 billion, compared to Eli Lilly's $6 billion. However, Eli Lilly has shown a remarkable growth trajectory, increasing its R&D spending by nearly 97% from 2014 to 2023. In 2023, Eli Lilly's R&D expenses surged to $9.3 billion, closing the gap with Pfizer, which spent $10.7 billion. This trend highlights Eli Lilly's aggressive push towards innovation, potentially reshaping the pharmaceutical landscape. As these giants continue to invest heavily in R&D, the future of medicine looks promising, with new breakthroughs on the horizon.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025